Dose-Intense Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Bendamustine; Fludarabine; Rituximab
- Indications Lymphoid leukaemia
- Focus Adverse reactions
- 14 May 2019 Status changed from active, no longer recruiting to completed.
- 24 Apr 2019 Planned End Date changed from 1 Jan 2019 to 1 Aug 2019.
- 24 Apr 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Aug 2019.